Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970527 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01970527 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 23 participants.
The verdict
NCT01970527, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage IV melanoma. Stereotactic body radiotherapy (SBRT) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as ipilimumab, target certain cells to interfere with the ability of tumor cells to grow and spread. Giving SBRT with ipilimumab may kill more tumor cells.
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Ipilimumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970527
The ClinicalTrials.gov registry entry for NCT01970527 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT01970527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970527 about?
NCT01970527 is a clinical study titled "Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma". This phase II trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage IV melanoma. Stereotactic body radiotherapy (SBRT) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as ipilimuma...
What is the current status of trial NCT01970527?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2014-03. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT01970527?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Ipilimumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01970527?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.